Safety and Tolerability of BI 409306 in Patients With Schizophrenia
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the current study is to investigate the safety and tolerability of
BI 409306 in schizophrenic patients following oral administration of multiple low, medium,
and high doses over 14 days.
A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics of BI
409306 in schizophrenic patients.